Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine

International Journal of Hyperthermia

Volumn 29, Issue 5, 2013, Pages 390-398

  Epple, Laura M ^a,b   Bemis, Lynne T ^c   Cavanaugh, Ryan P ^d   Skope, Anne ^d   Mayer Sonnenfeld, Tehila ^e   Frank, Chad ^a   Olver, Christine S ^a   Lencioni, Alex M ^b   Dusto, Nathaniel L ^b   Tal, Alona ^e   Har Noy, Michael ^e   Lillehei, Kevin O ^b   Katsanis, Emmanuel ^f   Graner, Michael W ^b  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d Alameda East Veterinary Hospital   (United States)

^e Immunovative Therapies Ltd   (Israel)

^f UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer vaccine; Canine lung tumour; Chaperone rich cell lysate; Heat shock proteins; Tumour immunity

Indexed keywords

BCG VACCINE; CANCER VACCINE; IMIQUIMOD;

ADVANCED CANCER; ARTICLE; ATAXIA; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DOG; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; EXOSOME; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; GENETIC ANALYSIS; IMMUNE RESPONSE; IMMUNOSTIMULATION; LANGERHANS CELL; LUNG ALVEOLUS CELL CARCINOMA; LUNG LOBE; LUNG LOBECTOMY; LUNG NODULE; LYMPH NODE METASTASIS; NYSTAGMUS; SURVIVAL TIME; THORACOTOMY; THORAX RADIOGRAPHY; WESTERN BLOTTING;

EID: 84881146403     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2013.800997     Document Type: Article

References (49)

1. Chen X, Zeng Y, Li G, Larmonier N, Graner MW, Katsanis E. Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. Biol Blood Marrow Transplant 2006;12:275-83. (Pubitemid 43273712)
2. Graner M, Raymond A, Akporiaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol Immunother 2000;49:476-84.
3. Graner M, Raymond A, Romney D, He L, Whitesell L, Katsanis E. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clin Cancer Res 2000;6: 909-15. (Pubitemid 30159348)
4. Graner MW, Zeng Y, Feng H, Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother 2003; 52:226-34. (Pubitemid 36535282)
5. Kislin KL, Marron MT, Li G, Graner MW, Katsanis E. Chaperonerich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. FASEB J 2007;21:2173-84. (Pubitemid 47026452)
6. Li G, Zeng Y, Chen X, Larmonier N, Sepassi M, Graner MW, et al. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clin Exp Immunol 2007;148: 136-45. (Pubitemid 46364991)
7. Zeng Y, Feng H, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 2003;101:4485-91. (Pubitemid 36857818)
8. Zeng Y, Graner MW, Katsanis E. Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunol Immunother 2006;55:329-38. (Pubitemid 41682582)
9. Feng H, Zeng Y, Graner MW, Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood 2002;100:4108-15. (Pubitemid 35396879)
10. Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood 2003;101: 245-52. (Pubitemid 36025914)
11. Graner MW, Romanoski A, Katsanis E. The 'peptidome' of tumourderived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. Int J Hyperthermia, epub ahead of print. DOI: 10.3109/02656736. 2013.793406.
12. Feng H, Zeng Y, Whitesell L, Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood 2001;97:3505-12.
13. Larmonier N, Cantrell J, Lacasse C, Li G, Janikashvili N, Situ E, et al. Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. J Leukoc Biol 2008;83:1049-59. (Pubitemid 351959886)
14. Li G, Andreansky S, Helguera G, Sepassi M, Janikashvili N, Cantrell J, et al. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. Mol Cancer Ther 2008;7:721-9. (Pubitemid 351482155)
15. Smith DF, Whitesell L, Katsanis E. Molecular chaperones: Biology and prospects for pharmacological intervention. Pharmacol Rev 1998;50:493-514.
16. Zeng Y, Chen X, Larmonier N, Li G, Sepassi M, Marron M, et al. Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination. Int J Cancer 2006;119:2624-31. (Pubitemid 44691318)
17. Schon M, Schon MP. The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr Med Chem 2007;14:681-7. (Pubitemid 46477720)
18. Shi C, Xiong Z, Chittepu P, Aldrich CC, Ohlfest JR, Ferguson DM. Discovery of imidazoquinolines with Toll-like receptor 7/8 independent cytokine induction. ACS Med Chem Lett 2012;3:501-4.
19. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Zitvogel L, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012;1:894-907.
20. Darieva ZA, Lasunskaia EB, Kipnis TL, Dias Da Silva W. Two BCG vaccine formulations prepared from the same strain with different J774 macrophage activation capacities and patterns of NFkappaB induction. Int J Mol Med 2000;6:575-80.
21. Magno C, Melloni D, Gali A, Mucciardi G, Nicocia G, Morandi B, et al. The anti-tumor activity of bacillus Calmette-Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2. Immunol Lett 2002;81:235-8. (Pubitemid 34310231)
22. Makino M, Mukai T. [Enhanced activation of T lymphocytes by urease-deficient recombinant bacillus Calmette-Guerin producing heat shock protein 70-major membrane protein-II fusion protein]. Nihon Hansenbyo Gakkai Zasshi 2012;81:199-203.
23. Saban MR, Hellmich HL, Simpson C, Davis CA, Lang ML, Ihnat MA, et al. Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits singlespanning uroplakins. BMC Cancer 2007;7:204.
24. Segawa N, Iwamoto Y, Azuma H, Yamamoto K, Ueda H, Katsuoka Y. [Intravesical BCG therapy for superficial bladder cancer]. Hinyokika Kiyo 1998;44:627-31. (Pubitemid 28489264)
25. Yamada H, Matsumoto S, Matsumoto T, Yamada T, Yamashita U. Murine IL-2 secreting recombinant bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J Urol 2000;164:526-31. (Pubitemid 30481978)
26. LaRue SM, Withrow SJ, Wykes PM. Lung resection using surgical staples in dogs and cats. Vet Surg 1987;16:238-40.
27. Polton GA, Brearley MJ, Powell SM, Burton CA. Impact of primary tumour stage on survival in dogs with solitary lung tumours. J Small Anim Pract 2008;49:66-71. (Pubitemid 351177883)
28. McNiel EA, Ogilvie GK, Powers BE, Hutchison JM, Salman MD, Withrow SJ. Evaluation of prognostic factors for dogs with primary lung tumors: 67 cases (1985-1992). J Am Vet Med Assoc 1997; 211:1422-7. (Pubitemid 127470968)
29. Ogilvie GK, Haschek WM, Withrow SJ, Richardson RC, Harvey HJ, Henderson RA, et al. Classification of primary lung tumors in dogs: 210 cases (1975-1985). J Am Vet Med Assoc 1989;195: 106-8.
30. Ogilvie GK, Weigel RM, Haschek WM, Withrow SJ, Richardson RC, Harvey HJ, et al. Prognostic factors for tumor remission and survival in dogs after surgery for primary lung tumor: 76 cases (1975-1985). J Am Vet Med Assoc 1989;195:109-12.
31. Poirier VJ, Burgess KE, Adams WM, Vail DM. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med 2004;18:536-9. (Pubitemid 39107545)
32. Zeng Y, Graner MW, Feng H, Li G, Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat BCR-ABL+ murine leukemia. Int J Cancer 2004;110:251-9. (Pubitemid 38580399)
33. Epple LM, Griffiths SG, Dechkovskaia AM, Dusto NL, White J, Ouellette, RJ, et al. Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles. PLoS One 2012;7: e42064.
34. Vegran F, Rebucci M, Chevrier S, Cadouot M, Boidot R, Lizard-Nacol S. Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma. PLoS One 2013;8:e55103.
35. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996;42:858-68.
36. Lee CH, Kim WH, Lim JH, Kang MS, Kim DY, Kweon OK. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. J Vet Sci 2004;5:63-9.
37. Lee CH, Kweon OK. Mutations of p53 tumor suppressor gene in spontaneous canine mammary tumors. J Vet Sci 2002;3:321-5.
38. York D, Higgins RJ, LeCouteur RA, Wolfe AN, Grahn R, Olby N, et al. TP53 mutations in canine brain tumors. Vet Pathol 2012;49: 796-801.
39. Kirpensteijn J, Kik M, Teske E, Rutteman GR. TP53 gene mutations in canine osteosarcoma. Vet Surg 2008;37:454-60. (Pubitemid 352000190)
40. Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, et al. Phase III comparison of vitespen, an autologous tumorderived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 Study Group. J Clin Oncol 2008;26:955-62. (Pubitemid 351398090)
41. Manjili MH, Henderson R, Wang XY, Chen X, Li Y, Repasky E, et al. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res 2002;62: 1737-42. (Pubitemid 34408496)
42. Manjili MH, Park J, Facciponte JG, Subjeck JR. HSP110 induces 'danger signals' upon interaction with antigen presenting cells and mouse mammary carcinoma. Immunobiology 2005;210:295-303. (Pubitemid 41102638)
43. Wang XY, Kazim L, Repasky EA, Subjeck JR. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J Immunol 2001;166:490-7. (Pubitemid 32038468)
44. Wang XY, Kazim L, Repasky EA, Subjeck JR. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+T-cell responses and reduces pulmonary metastatic disease. Int J Cancer 2003;105:226-31. (Pubitemid 36505326)
45. Wang XY, Manjili MH, Park J, Chen X, Repasky E, Subjeck JR. Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins. Methods 2004;32:13-20. (Pubitemid 37421174)
46. Wang XY, Yi H, Yu X, Zuo D, Subjeck JR. Enhancing antigen cross-presentation and T-cell priming by complexing protein antigen to recombinant large heat-shock protein. Methods Mol Biol 2011;787:277-87.
47. Itoh H, Horiuchi Y, Nagasaki T, Sakonju I, Kakuta T, Fukushima U, et al. Evaluation of immunological status in tumor-bearing dogs. Vet Immunol Immunopathol 2009;132:85-90.
48. Sottnik JL, Rao S, Lafferty MH, Thamm DH, Morley PS, Withrow SJ, et al. Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcoma. J Vet Intern Med 2010;24:1439-44.
49. Igney FH, Krammer PH. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 2002;71:907-20.